Flow cytometry is a technology that can be used to rapidly analyze physical and chemical properties of individual cells. It is a powerful tool with many applications in multiple disciplines such as blood cancers, immunology, molecular biology, and cellular therapy. For example, it is very effective for the study of the immune system and its response to infectious diseases and cancer.
CRP and sCD25 help distinguish between adult-onset Still's disease and HLH
European Journal of Haematology
DOI: 10.1111/ejh.14267
2024
A sinister case of pseudothrombocytosis
British Journal of Haematology
DOI: 10.1111/bjh.19566
2024
Monolobated megakaryocytes in Diamond–Blackfan anemia with RPL5 mutation at disease presentation mimicking myelodysplastic syndrome
Pediatric Blood and Cancer
DOI: 10.1002/pbc.30771
2024
Expanding the molecular and phenotypic spectrum of CTLA-4 insufficiency
Pediatric Allergy and Immunology
DOI: 10.1111/pai.14077
2024
The role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset Still’s disease, and COVID-19 cytokine storm
Research Square
DOI: 10.21203/rs.3.rs-4798637/v1
2024
Monolobated Megakaryocytes in Diamond Blackfan Anemia with RPL5 Mutation at Disease Presentation Mimicking Myelodysplastic Syndrome
Audi Setiadi and Claudia Singh and Amanda Li and Nicholas Au and Ali Amid
DOI: 10.22541/au.169468925.50466482/v1
09/2023
Homozygous RMRP Promoter Duplications Cause Severely Reduced Transcript Abundance and SCID Associated with Cartilage Hair Hypoplasia
Journal of Clinical Immunology
DOI: 10.1007/s10875-023-01489-5
2023
A longitudinal single-cell atlas of treatment response in pediatric AML
Cancer Cell
DOI: 10.1016/j.ccell.2023.10.008
2023
A germline heterozygous dominant negative IKZF2 variant causing syndromic primary immune regulatory disorder and ICHAD
medRxiv
DOI: 10.1101/2023.09.09.23295301
2023
Human ASXL1 Deficiency Causes Epigenetic Dysfunction, Combined Immunodeficiency and EBV–Associated Hodgkin Lymphoma
medRxiv
DOI: 10.1101/2023.12.20.23300096
2023
Targeted treatment of immune thrombocytopenia in CTLA-4 insufficiency: a case report
British Journal of Haematology
Lai, C.M.B. and Setiadi, A. and Barlas, A. and Kanani, A. and Pourshahnazari, P. and Leitch, H.A. and Metzger, D.L. and Merkeley, H. and Biggs, C.M.
DOI: 10.1111/bjh.17866
2022
Malignancy-associated haemophagocytic lymphohistiocytosis
The Lancet Haematology
Setiadi, A. and Zoref-Lorenz, A. and Lee, C.Y. and Jordan, M.B. and Chen, L.Y.C.
DOI: 10.1016/S2352-3026(21)00366-5
2022
Human germline biallelic complete NFAT1 deficiency causes the triad of progressive joint contractures, osteochondromas, and susceptibility to B cell malignancy
medRxiv
Sharma, M. and Fu, M.P. and Lu, H.Y. and Sharma, A.A. and Modi, B.P. and Michalski, C. and Lin, S. and Dalmann, J. and Salman, A. and Del Bel, K.L. and Waqas, M. and Terry, J. and Setiadi, A. and Lavoie, P.M. and Wasserman, W.W. and Mwenifumbo, J. and Kobor, M.S. and Lee, A.F. and Lehman, A. and Cheng, S. and Cooper, A. and Patel, M.S. and Turvey, S.E.
DOI: 10.1101/2022.01.30.22269378
2022
COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes
The Lancet Infectious Diseases
Spaner, C. and Goubran, M. and Setiadi, A. and Chen, L.Y.C.
DOI: 10.1016/S1473-3099(22)00348-6
2022
Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis
Cytometry Part B - Clinical Cytometry
Shopsowitz, K.E. and Liu, L. and Setiadi, A. and Al-Bakri, M. and Vercauteren, S.
DOI: 10.1002/cyto.b.22084
2022
Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy
Blood
Sharma, M. and Fu, M.P. and Lu, H.Y. and Sharma, A.A. and Modi, B.P. and Michalski, C. and Lin, S. and Dalmann, J. and Salman, A. and Del Bel, K.L. and Waqas, M. and Terry, J. and Setiadi, A. and Lavoie, P.M. and Wasserman, W.W. and Mwenifumbo, J. and Kobor, M.S. and Lee, A.F. and Kuchenbauer, F. and Lehman, A. and Cheng, S. and Cooper, A. and Patel, M.S. and Turvey, S.E.
DOI: 10.1182/blood.2022015674
2022
Circulating rhabdoid tumor cells in the peripheral blood of a neonate
American Journal of Hematology
Al-Bakri, M. and Terry, J. and Chipperfield, K. and Morrison, D. and Setiadi, A.
DOI: 10.1002/ajh.26624
2022
T-lymphoblastic transformation of chronic myeloid leukemia
eJHaem
Maryam Al Bakri and Audi Setiadi
DOI: 10.1002/jha2.125
02/2021
Clinical and laboratory features associated with myeloperoxidase expression in pediatric B-lymphoblastic leukemia
Cytometry Part B - Clinical Cytometry
McGinnis, E. and Yang, D. and Au, N. and Morrison, D. and Chipperfield, K.M. and Setiadi, A.F. and Liu, L. and Tsang, A. and Vercauteren, S.M.
DOI: 10.1002/cyto.b.21966
2021
EDTA-induced platelet hypogranulation: beware of dysplasia mimic!
Journal of Hematopathology
Al Moosawi, M. and Vawda, A. and Setiadi, A.
DOI: 10.1007/s12308-021-00445-9
2021
CD138-negative plasma cell myeloma: A diagnostic challenge and a unique entity
BMJ Case Reports
Setiadi, A.F. and Sheikine, Y.
DOI: 10.1136/bcr-2019-232233
2019
The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia
International Journal of Laboratory Hematology
Setiadi, A. and Owen, D. and Tsang, A. and Milner, R. and Vercauteren, S.
DOI: 10.1111/ijlh.12535
2016
Notch Initiates the Endothelial-to-Mesenchymal Transition in the Atrioventricular Canal through Autocrine Activation of Soluble Guanylyl Cyclase
Developmental Cell
Chang, A. and Fu, Y. and Garside, V. and Niessen, K. and Chang, L. and Fuller, M. and Setiadi, A. and Smrz, J. and Kyle, A. and Minchinton, A. and Marra, M. and Hoodless, P. and Karsan, A.
DOI: 10.1016/j.devcel.2011.06.022
2011
Differential regulation of transforming growth factor ß signaling pathways by notch in human endothelial cells
Journal of Biological Chemistry
Fu, Y.X. and Chang, A. and Chang, L. and Niessen, K. and Eapen, S. and Setiadi, A. and Karsan, A.
DOI: 10.1074/jbc.M109.011833
2009
Minimal Residual Disease & Leukemic Stem Cells
Minimal residual disease refers to a small number of malignant cells that remain in the patient during or after treatment when the patient has no signs or symptoms of the disease. Flow cytometry allows for MRD analysis by looking at different expression of cellular antigens on malignant cells compared to normal cells. As part of Dr. Suzanne Vercauteren’s team, our lab has implemented 10-color flow cytometry panels for MRD detection in B-cell acute lymphoblastic leukemia (the most common type of blood cancer in children) post chemotherapy and post CD19 directed therapy. In collaboration with the BRAVe initiative, we are currently looking at more markers to identify leukemic stem cell populations, which may contribute to relapse or treatment resistance.
Primary Immunodeficiency Disorders and Hemophagocytic Lymphohistiocytosis
PIDDs are a heterogeneous group of inherited disorders resulting from genetic defects that impair the immune system. Given the complexity of the immune system, the clinical manifestations of PIDDs are highly variable and may present with recurrent infections, autoimmunity and predisposition to cancer. Under the “Diseases of Immune Dysregulation” group of PIDD is a life threatening disorder called Hemophagocytic Lymphohistiocytosis (HLH), leading to an overactive, dysfunctional response of immune system, low blood cell counts and multi-organ damage. Our lab implemented clinical flow cytometry panels to support newborn screening for severe combined immunodeficiency (SCID) and expand the investigation for PIDD, as well as Perforin assay for screening of primary HLH. We continue to optimize our assay methodologies and reference ranges to support the diagnosis of PIDD in BC.
Cellular Therapy
Our lab is validating several flow cytometry panels for product assessment of several graft engineering projects under TRACE initiative, including T-cell alpha/beta depleted stem cell transplantation to reduce GvHD risk, as well as viral specific T-cell therapy for severe protracted viral infection post-transplant.
Michelle Dittrick, Clinical Research Program Manager
A pan-Canadian team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumours in chicken eggs and analyzing their proteins.
The team, led by researchers from BC Children’s Hospital Research Institute and the University of British Columbia, is the first in Canada to combine these two techniques to identify and test a drug for a young patient's tumour in time for their treatment.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.